Telotristat ethyl (TE), which is an oral inhibitor of Tph1, has been approved by the United States Food and Drug Administration (US FDA) to relieve diarrhea symptoms in patients with carcinoid syndrome [210]. Here, TPH1 is linked to carcinoid syndrome.